Gastrointestinal (GI)
Study Name: Circulate
- Cancer Stage: IIb, IIc, III
- Key Inclusion: MSI stable
- Description: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease in Patients with Stage IIB, IIC, or Stage III Colon Adenocarcinoma with R0 Resection (CIRCULATE-US).
- Study Number: NRG-GI008
- NCT#: NCT05174169
Study Name: origAMI-2
- Cancer Stage: IV
- Key Inclusion: First line unresectable or metatstaic left saided CRC
- Description: Compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma RAS viral oncogene homolog (NRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) wild type (WT) unresectable or metastatic left-sided colorectal cancer.
- Study Number: 61186372COR3001
- NCT#: NCT06662786
Study Name: origAMI-3
- Cancer Stage: N/A
- Key Inclusion: Recurrent, unresectable or metastatic colon cancer w/ 1 previous line
- Description: Compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.
- Study Number: 61186372COR3002
- NCT#: NCT06750094